TP53 and hepatocellular carcinoma: Due to the gene and molecular-related proliferative activity (e.g., TP53 mutations, FGF19 amplification, and chromosomal instability), MTM-HCC represents an aggressive form of HCC that is associated with poor clinical prognosis, especially early recurrence (4–6).